Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Q2 2024 Earnings Presentation
17 slides from Hansa Biopharma Ab's earnings presentation, Jul 18, 2024
Slide 1: Interim Report
> HANS BIOPHARM Interim Report July 18, 2024
Slide 2: Forward-looking statements
Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occ
Slide 3: Interim Results Conference Call Agenda
Interim Results Conference Call Agenda 18 July 2024 CEO Remarks Søren Tulstrup Chief Executive Officer, President Operational Update Matt Shaulis Chief Commercial Officer Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Q&A and Close Søren Tu
Slide 4: Delivering on priorities across the business
Delivering on priorities across the business STEADY COMMERCIAL MOMENTUM NOTABLE PIPELINE PROGRESS 3rd consecutive quarter of strong sales* ConfIdeS fully randomized; data in 2H 2025 Year to Date 2Q 2024 US ConfIdeS Phase 3 trial - fully randomized 94.6 MSEK 47.1 MSEK IDEFIRIX Sales IDEFIRIX Sales An
Slide 5: Operational Update
Interim Results Conference 18 July 2024 CEO Remarks Søren Tulstrup Chief Executive Officer, President Operational Update Matt Shaulis Chief Commercial Officer Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Q&A and Close Søren Tulstrup Chief
Slide 6: In-market growth and clinical utilization continue to drive IDEFIRIX EU launch
In-market growth and clinical utilization continue to drive IDEFIRIX® EU launch Ø Reimbursement in 14 Ø 7 countries issued clinical Ø 28 centers with clinical markets including 5 guidelines experience largest EU markets Ø April ESOT consensus Ø First commercial sales in Ø Access in 75% of EU paper r
Slide 7: Advancing imlifidase's profile in transplantation with additional trial data
Advancing imlifidase’s compelling profile in transplantation with additional trial data Long-term follow-up study Post approval efficacy study (PAES) 17-HMedIdeS-14 20-HMedIdeS-19 Positive results of extended-pooled analysis from 17- Open label Phase 3 study to confirm the long-term HMedIdeS-14 and
Slide 8: US ConfIdeS trial is fully randomized; data read-out in 2H 2025
US ConfIdeS trial is fully randomized; anticipated data read-out in 2H 2025 • Pivotal Phase 3 US trial ABOUT • Open-label, controlled, randomized trial evaluating 12-month kidney function in highly sensitized CONFIDES kidney transplant patients with positive crossmatch against a deceased donor • Wil
Slide 9: Pipeline Update
Interim Results Conference 18 July 2024 CEO Remarks Søren Tulstrup Chief Executive Officer, President Operational Update Matt Shaulis Chief Commercial Officer Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Q&A and Close Søren Tulstrup Chief
Slide 10: Key pipeline progress and a look ahead
Key pipeline progress and a look ahead Progress to date What’s next 2H ’24 Looking ahead - 2025 • COMPLETED NICE-01 Ph 1 • HNSA-5487 Ph 1 data on exploratory • HNSA-5487 clinical development EARLY DEV safety/tolerability for HNSA-5487 endpoints and clinical development path • FULL RANDOMIZATION Conf
Slide 11: Financial Results
Interim Results Conference 18 July 2024 CEO Remarks Søren Tulstrup Chief Executive Officer, President Operational Update Matt Shaulis Chief Commercial Officer Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Q&A and Close Søren Tulstrup Chief
Slide 12: Strong commercial performance with total Q2 product sales of 47 MSEK offset by provision
Strong commercial performance with total Q2 product sales of 47 MSEK offset by provision totaling 19.9 MSEK Revenue (Q/Q) Product Sales (Q/Q) Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 56.0 54.2 50.4 47.1 Product sales (excl. provision) Product sales 47.1 MSEK (excl. provision) MSEK
Slide 13: Continued investments in commercialization and R&D activities
Continued investments in commercialization and R&D activities SG&A expenses (Q/Q) R&D expenses (Q/Q) Operating loss (Q/Q) Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 -176 -159 -88 MSEK MSEK -91 -92 -187 MSEK -129 -96 -103 -202 -112 -106 -115 -108 -228 SG
Slide 14: Cash runway into 2026 through directed share issue
Cash runway into 2026 through directed share issue Operating cash flow (Q/Q) Cash & short-term investments (Q/Q) Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 1,103 MSEK 908 MSEK 732 705 -183 -173 -193 -189 -189 541 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Operating cash flow (1H/1H) Number of employees (Q/Q) 2022 2023 2024 1
Slide 15: Q&A and Close
Interim Results Conference 18 July 2024 CEO Remarks Søren Tulstrup Chief Executive Officer, President Operational Update Matt Shaulis Chief Commercial Officer Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Q&A and Close Søren Tulstrup Chief
Slide 16: Hansa Biopharma contacts and key events
Hansa Biopharma contacts and key events Contacts Calendar and events Evan Ballantyne 2024 Chief Financial Officer 9 SEPT HC Wainwright 26th Annual Global Investment Email: ir@hansabiopharma.com Conference, NY 24 OCT Q3 2024 (July-September) Report 18-19 NOV SEB Healthcare Seminar, Stockholm Stephani
Slide 17: HAN Sar
MZ HAN Sar BIOPHARMA